Document Detail


Assessment of dose selection attributes with audible notification in insulin pen devices.
MedLine Citation:
PMID:  16120036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Patients with type 2 diabetes often suffer from impairments in vision as well as manual dexterity. The purpose of this study was to assess the reliability of dose selection and setting of five insulin devices by patients using auditory and sensory confirmation. METHODS: A total of 48 patients (30 men, 18 women; mean +/- SD age 60.5 +/- 14.0 years; hemoglobin A(1c) 8.7 +/- 1.9%) were randomized to test the following devices: NovoPen 3 (Novo Nordisk A/S, Bagsvaerd, Denmark), HumaPen Ergo (Eli Lilly, Indianapolis, IN), Humalog Pen (Eli Lilly), InnoLet (Novo Nordisk), and FlexPen(Novo Nordisk). RESULTS: Significantly more patients detected an auditory confirmation of dose setting when using the NovoPen 3 compared with the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The audible click for the FlexPen was also heard by more patients than for the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). All patients found that the Flex- Pen provided physical sensory confirmation; the percentage was higher than for those using the Humalog Pen (P < 0.001), HumaPen Ergo (P < 0.001), and InnoLet (P < 0.01). The NovoPen 3 was also associated with a higher percentage of patients who felt the click sensation than with the Humalog Pen (P < 0.001) and HumaPen Ergo (P < 0.01). Patients reported more confidence in setting the correct dose with the NovoPen 3 and FlexPen, and found these the most reliable for dose setting. Sound recordings showed that the NovoPen 3 produced the loudest clicks when setting a dose (P < 0.001 for all comparisons). CONCLUSIONS: The clarity of the click when setting a dose on an insulin delivery device can affect the patient's confidence in selecting the correct dose.
Authors:
Toshinari Asakura; Hiroaki Seino
Related Documents :
1086266 - How to detect and treat arrhythmias in chronic lung disease.
17276446 - Electrophysiologic characteristics and outcome of segmental ostial superior vena cava i...
20675996 - The efficiency and safety of percutaneous closure of secundum atrial septal defects wit...
361226 - Phase i clinical study of quelamycin.
20847416 - Decline of human tactile angle discrimination in patients with mild cognitive impairmen...
21303486 - Impact of c1q deficiency on the severity and outcome of childhood systemic lupus erythe...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  7     ISSN:  1520-9156     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-25     Completed Date:  2005-11-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  620-6     Citation Subset:  IM    
Affiliation:
Department of Pharmacy, Ohta Nishinouchi Hospital, 2-5-20 Nishinouchi, Koriyama, Fukushima-ken 963-8558, Japan. asa-mac@m7.dion.ne.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Automation
Blindness / prevention & control
Diabetes Mellitus / drug therapy*
Diabetic Retinopathy / prevention & control
Equipment Design
Female
Humans
Injections, Subcutaneous / instrumentation*
Insulin / administration & dosage*,  therapeutic use
Male
Middle Aged
Touch
Chemical
Reg. No./Substance:
11061-68-0/Insulin
Comments/Corrections
Comment In:
Diabetes Technol Ther. 2005 Aug;7(4):627-8   [PMID:  16120037 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Invasiveness as a barrier to self-monitoring of blood glucose in diabetes.
Next Document:  Force requirements and insulin delivery profiles of four injection devices.